Compare SUNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | SCYX |
|---|---|---|
| Founded | 2023 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.7M | 26.5M |
| IPO Year | N/A | 2014 |
| Metric | SUNS | SCYX |
|---|---|---|
| Price | $10.26 | $0.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.50 | $3.00 |
| AVG Volume (30 Days) | 89.8K | ★ 469.7K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | ★ 11.65% | N/A |
| EPS Growth | ★ 1112.46 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $19,384,703.00 | $2,932,000.00 |
| Revenue This Year | $174.58 | $167.73 |
| Revenue Next Year | $60.45 | $290.78 |
| P/E Ratio | $9.44 | ★ N/A |
| Revenue Growth | ★ 2540.16 | N/A |
| 52 Week Low | $7.80 | $0.57 |
| 52 Week High | $14.87 | $1.49 |
| Indicator | SUNS | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 43.25 |
| Support Level | $10.06 | $0.63 |
| Resistance Level | $10.45 | $0.67 |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 78.24 | 23.68 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.